Cargando…

Outcome of Sub-Massive Pulmonary Thromboemboli in Patients Who Received Thrombolytic and or Non-Thrombolytic Therapy

BACKGROUND: Thrombolytic therapy in patients with sub-massive pulmonary embolism (SMPTE) needs further assessment. OBJECTIVES: The current study aimed to assess a potential benefit of thrombolytic and non-thrombolytic therapy in patients with SMPTE. PATIENTS AND METHODS: One hundred-nineteen patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Sadeghi, Hasan Allah, Heidarali, Mona, Faraji, Fusieh, Ghadrdoost, Behshid, Shojaeifard, Maryam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kowsar 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075428/
https://www.ncbi.nlm.nih.gov/pubmed/29781474
http://dx.doi.org/10.5812/cardiovascmed.29638
_version_ 1782461860747935744
author Sadeghi, Hasan Allah
Heidarali, Mona
Faraji, Fusieh
Ghadrdoost, Behshid
Shojaeifard, Maryam
author_facet Sadeghi, Hasan Allah
Heidarali, Mona
Faraji, Fusieh
Ghadrdoost, Behshid
Shojaeifard, Maryam
author_sort Sadeghi, Hasan Allah
collection PubMed
description BACKGROUND: Thrombolytic therapy in patients with sub-massive pulmonary embolism (SMPTE) needs further assessment. OBJECTIVES: The current study aimed to assess a potential benefit of thrombolytic and non-thrombolytic therapy in patients with SMPTE. PATIENTS AND METHODS: One hundred-nineteen patients were enrolled with SMPTE from 2006 to 2010 in the tertiary care center of Rajaie medical and research center. The patients who had pulmonary thromboemboli (PTE) and received thrombolytic plus heparin therapy and or non-thrombolytic (unfractionated heparin alone) were evaluated for hemodynamic changes (blood pressure, pulse rate, pulmonary artery systolic pressure, right ventricular failure and right ventricle enlargement), before and after 48 hours of treatment. The mortality rate was also assessed. RESULTS: Forty-five percent of the patients with SMPTE received thrombolytic therapy (streptokinase) and 55% of SMPTE patients received non-thrombolytic therapy (unfractionated heparin). Pulse rate, pulmonary arterial pressure and tricuspid regurgitation gradient in patients receiving thrombolytic therapy reduced significantly (P = 0.001, P = 0.01 and P = 0.001, respectively). There was no significant difference before and after treatment regarding systolic blood pressure (P = 0.4), diastolic blood pressure (DBP) (P = 0.5), systolic arterial pressure (SPAP) (P = 0.1), Right ventricular (RV) function (P = 0.1) and RV size (P = 0.1). In patients who received a non-thrombolytic therapy, there were no significant differences between the groups regarding SBP (P = 0. 2), DBP ( P= 0. 4) and PR (P = 0. 1), SPAP (P = 0.6), TRG (P = 0.4), RV function (P = 0.4) and RV size (P = 0.2) before and after treatment. There were no significant differences between the groups according to mortality rate. CONCLUSIONS: Thrombolytic therapy lead to earlier relief of hemodynamic condition in comparison to non-thrombolytic therapy but no changes were observed in mortality rate.
format Online
Article
Text
id pubmed-5075428
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Kowsar
record_format MEDLINE/PubMed
spelling pubmed-50754282016-10-31 Outcome of Sub-Massive Pulmonary Thromboemboli in Patients Who Received Thrombolytic and or Non-Thrombolytic Therapy Sadeghi, Hasan Allah Heidarali, Mona Faraji, Fusieh Ghadrdoost, Behshid Shojaeifard, Maryam Res Cardiovasc Med Research Article BACKGROUND: Thrombolytic therapy in patients with sub-massive pulmonary embolism (SMPTE) needs further assessment. OBJECTIVES: The current study aimed to assess a potential benefit of thrombolytic and non-thrombolytic therapy in patients with SMPTE. PATIENTS AND METHODS: One hundred-nineteen patients were enrolled with SMPTE from 2006 to 2010 in the tertiary care center of Rajaie medical and research center. The patients who had pulmonary thromboemboli (PTE) and received thrombolytic plus heparin therapy and or non-thrombolytic (unfractionated heparin alone) were evaluated for hemodynamic changes (blood pressure, pulse rate, pulmonary artery systolic pressure, right ventricular failure and right ventricle enlargement), before and after 48 hours of treatment. The mortality rate was also assessed. RESULTS: Forty-five percent of the patients with SMPTE received thrombolytic therapy (streptokinase) and 55% of SMPTE patients received non-thrombolytic therapy (unfractionated heparin). Pulse rate, pulmonary arterial pressure and tricuspid regurgitation gradient in patients receiving thrombolytic therapy reduced significantly (P = 0.001, P = 0.01 and P = 0.001, respectively). There was no significant difference before and after treatment regarding systolic blood pressure (P = 0.4), diastolic blood pressure (DBP) (P = 0.5), systolic arterial pressure (SPAP) (P = 0.1), Right ventricular (RV) function (P = 0.1) and RV size (P = 0.1). In patients who received a non-thrombolytic therapy, there were no significant differences between the groups regarding SBP (P = 0. 2), DBP ( P= 0. 4) and PR (P = 0. 1), SPAP (P = 0.6), TRG (P = 0.4), RV function (P = 0.4) and RV size (P = 0.2) before and after treatment. There were no significant differences between the groups according to mortality rate. CONCLUSIONS: Thrombolytic therapy lead to earlier relief of hemodynamic condition in comparison to non-thrombolytic therapy but no changes were observed in mortality rate. Kowsar 2016-07-20 /pmc/articles/PMC5075428/ /pubmed/29781474 http://dx.doi.org/10.5812/cardiovascmed.29638 Text en Copyright © 2016, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences http://creativecommons.org/licenses/by-nc/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
spellingShingle Research Article
Sadeghi, Hasan Allah
Heidarali, Mona
Faraji, Fusieh
Ghadrdoost, Behshid
Shojaeifard, Maryam
Outcome of Sub-Massive Pulmonary Thromboemboli in Patients Who Received Thrombolytic and or Non-Thrombolytic Therapy
title Outcome of Sub-Massive Pulmonary Thromboemboli in Patients Who Received Thrombolytic and or Non-Thrombolytic Therapy
title_full Outcome of Sub-Massive Pulmonary Thromboemboli in Patients Who Received Thrombolytic and or Non-Thrombolytic Therapy
title_fullStr Outcome of Sub-Massive Pulmonary Thromboemboli in Patients Who Received Thrombolytic and or Non-Thrombolytic Therapy
title_full_unstemmed Outcome of Sub-Massive Pulmonary Thromboemboli in Patients Who Received Thrombolytic and or Non-Thrombolytic Therapy
title_short Outcome of Sub-Massive Pulmonary Thromboemboli in Patients Who Received Thrombolytic and or Non-Thrombolytic Therapy
title_sort outcome of sub-massive pulmonary thromboemboli in patients who received thrombolytic and or non-thrombolytic therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075428/
https://www.ncbi.nlm.nih.gov/pubmed/29781474
http://dx.doi.org/10.5812/cardiovascmed.29638
work_keys_str_mv AT sadeghihasanallah outcomeofsubmassivepulmonarythromboemboliinpatientswhoreceivedthrombolyticandornonthrombolytictherapy
AT heidaralimona outcomeofsubmassivepulmonarythromboemboliinpatientswhoreceivedthrombolyticandornonthrombolytictherapy
AT farajifusieh outcomeofsubmassivepulmonarythromboemboliinpatientswhoreceivedthrombolyticandornonthrombolytictherapy
AT ghadrdoostbehshid outcomeofsubmassivepulmonarythromboemboliinpatientswhoreceivedthrombolyticandornonthrombolytictherapy
AT shojaeifardmaryam outcomeofsubmassivepulmonarythromboemboliinpatientswhoreceivedthrombolyticandornonthrombolytictherapy